Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Market Place
ABOUT THIS PAGE
A Mavorixafor manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Mavorixafor, including repackagers and relabelers. The FDA regulates Mavorixafor manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Mavorixafor API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Mavorixafor manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Mavorixafor supplier is an individual or a company that provides Mavorixafor active pharmaceutical ingredient (API) or Mavorixafor finished formulations upon request. The Mavorixafor suppliers may include Mavorixafor API manufacturers, exporters, distributors and traders.
click here to find a list of Mavorixafor suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Mavorixafor as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Mavorixafor API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Mavorixafor as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Mavorixafor and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Mavorixafor NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Mavorixafor suppliers with NDC on PharmaCompass.
Mavorixafor Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Mavorixafor GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Mavorixafor GMP manufacturer or Mavorixafor GMP API supplier for your needs.
A Mavorixafor CoA (Certificate of Analysis) is a formal document that attests to Mavorixafor's compliance with Mavorixafor specifications and serves as a tool for batch-level quality control.
Mavorixafor CoA mostly includes findings from lab analyses of a specific batch. For each Mavorixafor CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Mavorixafor may be tested according to a variety of international standards, such as European Pharmacopoeia (Mavorixafor EP), Mavorixafor JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Mavorixafor USP).
LOOKING FOR A SUPPLIER?
